Table 1.
Overlapping and differing characteristics of hepatic encephalopathy in ALF and CLD.
| NGVU disturbance | ALF/CLD overlap | ALF/CLD difference |
|---|---|---|
| Disturbed energy metabolism | CLD: Deficient ketone body production in the cirrhotic liver, insufficient to compensate for glucose allocation to the immune system[46], [47], [48], [49]; Lactate elevation is inconsistent51,54 | |
| Blood-brain barrier disruption | ALF: Barrier integrity disruption results in vasogenic brain oedema50,52; MMP9 mediates breakdown of tight junctions63,72,73 | |
| CLD: Evidence regarding BBB permeability, structure and tight junction alterations is inconsistent[67], [68], [69], [70] | ||
| Astrocyte swelling | ALF: Cellular swelling results in clinically significant brain oedema50,52; Hyperactivation of the ion channels NKCC1 and SUR1 creates ionic imbalances across the cell membrane and attracts water into the cell[93], [94], [95] | |
| CLD: Compensatory decrease of myoinositol and other osmolytes51,54,89; Low grade cerebral oedema of unclear clinical significance52 | ||
| Oxidative stress | CLD: Possible disconnect, with only systemic oxidative stress in the absence of cerebral oxidative stress68; Senescence only studied in vitro and in patients with CLD111,113,116 | |
| Neuroinflammation |
|
ALF: TGFβ1144 and bile acids124 can contribute to microglial activation in mouse models of ALF |
| Glymphatic clearance | CLD: Decreased glymphatic clearance leads to neuroinflammation in BDL rats101,122 |
ALF, acute liver failure; AQP4, aquaporin 4; BBB, blood-brain barrier; BCRP, breast cancer resistance protein; BDL, bile duct ligated; CLD, chronic liver disease; MMP9, matrix metalloproteinase 9; NKCC1, Na-K-2Cl cotransporter 1; SUR1, sulfonylurea receptor-1; TGFβ1, transforming growth factor β1; TNF, tumour necrosis factor